onesource

Building for the Future



19th Annual General Meeting (AGM)

September 23rd, 2026

(The new way to CDMO)

Safe Harbor Statement

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the forward- looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

onesource

A majority independent board provides oversight backed by deep global pharma and governance expertise



Arun Kumar
Chairperson and
Non-Executive Director



Debarati Sen
Non-Executive,
Independent Director



Dr. Claudio Albrecht
Non-Executive,
Independent Director




Colin Bond
Non-Executive,
Independent Director



Dr. Rashmi Barbhaiya
Non-Executive,
Independent Director



Vijay Karwal
Non-Executive,
Independent Director



Bharat Shah
Non-Executive
Director



Neeraj Sharma
Chief Executive Officer
and Managing Director

Building a specialty CDMO platform with offerings across complex modalities

onesource

ONE-OF-A-KIND INTEGRATED CDMO PLATFORM	INDUSTRY-LEADING MANUFACTURING CAPACITIES	ROBUST DEMAND ACROSS A DIVERSIFIED CUSTOMER BASE	BUILT ON TALENT AND TRUST
Leading Multi-Modality CDMO Platform in India	**5** State-of-the-Art Facilities	**70+** Active RFPs in Pipeline	**1,700+** Workforce
4 Offerings – DDC, Biologics, Sterile Injectables, and Oral Technologies (Softgel)	**$100M** Announced Capex Programme	**80+** Customers Across Modalities	**30+ years** Quality and Operational Excellence

Expanded customer partnerships, advanced capacity expansion, and building our biologics footprint

Last 15 Months

30+ Launches
7+ Markets Served

10+ New Logos
80+ Customers

$100M Capex
Phase 1 Completed

Leadership in DDC

4
G7 Semaglutide approvals
First & only CDMO

20+
Customer across modalities

- Semaglutide launched: Canada, India, Saudi Arabia
- 2 Tirzepatide FTFs secured in US
- Phase 2 capacity expansion in full swing

Building Biologics Business

5
New partnerships

4x
Active RFP funnel

- Expanding opportunity funnel driven by repeat business and new customer wins
- Multi-year programmes spanning development through commercialisation

Deepening Base Businesses

2x
Vial capacity expansion

5B caps
Independent greenfield softgel site


- Significant debottlenecking and capacity expansion across injectable business
- New greenfield site for softgels – additional capacity and new capability (high potency)

onesource

Building a quality-first organisation

Our Quality Policy

Quality is our responsibility and our promise. We design it into every process, deliver it in every product, and uphold it through our systems – always meeting global standards and exceeding customer expectations.



FDA · Health Canada · ANVISA · TGA Health Safety Regulation · European Medicines Agency · ... and many more

Consistent quality, compliance, and supply track record across all sites

onesource

FY26 a transition year; expanding capability and capacity to deliver FY27 and beyond

In $ m	FY26	FY25	YoY
Revenue	158.1	160.7	(2%)
EBITDA	33.8	51.9	(35%)
EBITDA margin (%)	21%	32%	(1089bps)
Reported PAT	(8.2)	(1.9)	--
Adjusted PAT[1]	8.2	25.7	(68%)
Adjusted EPS[1] ($)	0.07	0.23	(69%)

In ₹ m	FY26	FY25	YoY
Revenue	14,216	14,449	(2%)
EBITDA	3,042	4,665	(35%)
EBITDA margin (%)	21%	32%	(1089bps)
Reported PAT	(738)	(173)	--
Adjusted PAT[1]	739	2,314	(68%)
Adjusted EPS[1] (₹)	6.5	21.0	(69%)

Notes: All figures presented in $ have been converted using average exchange rate of USD = ₹89.898 and accordingly the prior period figures have been restated
1. Adjusted PAT and Adjusted EPS excludes exceptional items (FY26: ₹99m, FY25: ₹1,108m) and scheme related intangible amortisation (FY26: ₹1,378m, FY25: ₹1,413m)

Financial Snapshot

- **Full-year revenue declined marginally by 2% YoY**, reflecting a softer second half impacted by delayed semaglutide approvals in Canada
- **Full year EBITDA declined 35% YoY**, reflecting a high MSA base in prior year and an elevated cost base in FY26 as the DDC facility ramped up, partially offset by the semaglutide commercial launch
- **Impact of New Labour code** fully provided in FY26 financials

Q1FY27: Performance driven by semaglutide ramp-up delivering 39% YoY EBITDA growth

In $ m	Q1FY27	QoQ	Q1FY26	YoY
Revenue	**47.5**	+5%	34.6	+37%
EBITDA	**13.1**	+34%	9.4	+39%
EBITDA margin (%)	**27.5%**	+600bps	27.0%	+43bps
Reported PAT	**2.6**	5x+	(0.0)	Loss to Profit
Adjusted PAT[1]	**6.7**	+63%	3.9	+72%
Adjusted EPS[1] ($)	**0.06**	+63%	0.03	+71%

In ₹ m	Q1FY27	QoQ	Q1FY26	YoY
Revenue	**4,490**	+5%	3,273	+37%
EBITDA	**1,233**	+34%	885	+39%
EBITDA margin (%)	**27.5%**	+600bps	27.0%	+43bps
Reported PAT	**250**	5x+	(2)	Loss to Profit
Adjusted PAT[1]	**637**	+63%	371	+72%
Adjusted EPS[1] (₹)	**5.6**	+63%	3.2	+71%

Notes: All figures presented in $ have been converted using average exchange rate of USD = ₹94.507 and accordingly the prior period figures have been restated
1. Adjusted PAT and Adjusted EPS excludes exceptional items (Q1FY27: ₹43m, Q1FY26: ₹29m) and scheme related intangible amortisation (₹344m in each quarter)

Financial Snapshot

- **Revenue of $47.5m/₹4,490m**
  ↑5% QoQ and ↑37% YoY
  driven by growth in semaglutide commercial launch, new MSA contracts, and customer wins across businesses

- **EBITDA of $13.1m/₹1,233m**
  ↑ 34% QoQ and ↑ 39% YoY
  with margins expanding to **27.5%**, driven by operating leverage on higher semaglutide revenue

onesource

Building for sustainable value creation

Environmental

✓ 81% renewable energy contribution

✓ 100% Zero Liquid Discharge across our manufacturing sites

Social

✓ Zero work-related injuries; zero fatalities

✓ ₹22 million spent on CSR activities

Governance

✓ 98% average board meeting attendance

✓ 5/8 independent directors

EXTERNAL RATINGS

73/100
NSE Sustainability Rating
'Leader' category

64/100
EcoVadis Score
+7 pts YoY

B
CDP Score
2nd consecutive year

ADVANCING ESG PRACTICES

- Integrated Reporting
- Human rights assessment
- Supplier ESG assessment
- Climate risk assessment

First year of assurance on GRI-aligned indicators, beyond the mandatory BRSR Core

Agenda for AGM FY26

Ordinary Business	**Item 1:** To consider and adopt the audited financial statements (including consolidated financial statements) of the Company for the financial year ended March 31, 2026, and the reports of the Board of Directors and Auditors thereon
	Item 2: Re-appointment of Neeraj Sharma, retiring by rotation
Special Business	**Item 3:** Appointment and fixation of remuneration of Statutory Auditors - M/s. B S R & Co LLP
	Item 4: Additional remuneration payable to Neeraj Sharma, Managing Director for financial year ended March 31, 2026
	Item 5: Commission payable to Non-Executive Independent Directors of the Company
	Item 6: Approval of material Related Party Transactions (RPTs) of the Company with Strides Pharma Science Limited
	Item 7: Approval of material Related Party Transactions (RPTs) of the Company with Strides Pharma Inc, USA, (Wholly owned subsidiary of Strides Pharma Science Limited)

onesource

THE NEW WAY TO CDMO

Get in touch with us

REGISTERED AND CORPORATE OFFICE

OneSource Specialty Pharma Ltd

Registered Office:
Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A,
Vashi, Navi Mumbai, Sanpada, Thane,
Maharashtra, India, 400703
T: +91 22 2789 2924
F: +91 22 2789 2942

Corporate Office:
OneSource Specialty Pharma Limited
Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road,
Bengaluru, India, 560076
T: +91 80 6784 0738

www.onesourcecdmo.com

INVESTOR RELATIONS

Investor-relations@onesourcecdmo.com